KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Notes Payables (2018 - 2024)

Historic Notes Payables for Amneal Pharmaceuticals (AMRX) over the last 5 years, with Q1 2024 value amounting to $41.9 million.

  • Amneal Pharmaceuticals' Notes Payables changed N/A to $41.9 million in Q1 2024 from the same period last year, while for Mar 2024 it was $41.9 million, marking a year-over-year change of. This contributed to the annual value of $41.4 million for FY2023, which is 438.47% up from last year.
  • Amneal Pharmaceuticals' Notes Payables amounted to $41.9 million in Q1 2024.
  • Amneal Pharmaceuticals' Notes Payables' 5-year high stood at $41.9 million during Q1 2024, with a 5-year trough of $1.0 million in Q1 2020.
  • Its 4-year average for Notes Payables is $23.2 million, with a median of $39.7 million in 2022.
  • Data for Amneal Pharmaceuticals' Notes Payables shows a peak YoY increase of 438.47% (in 2023) and a maximum YoY decrease of 438.47% (in 2023) over the last 5 years.
  • Amneal Pharmaceuticals' Notes Payables (Quarter) stood at $1.0 million in 2020, then surged by 3870.6% to $39.7 million in 2022, then rose by 4.38% to $41.4 million in 2023, then increased by 1.08% to $41.9 million in 2024.
  • Its last three reported values are $41.9 million in Q1 2024, $41.4 million for Q4 2023, and $41.0 million during Q3 2023.